Show
Sort by
-
Effect of late-onset on multiple sclerosis phenotype and outcome : evidence from a multi-national registry
-
Explainable time-to-progression predictions in multiple sclerosis
-
- Journal Article
- A1
- open access
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data
-
Standardized definition of Progression Independent of Relapse Activity (PIRA) in relapsing-remitting multiple sclerosis
-
- Journal Article
- A1
- open access
Disease activity in pregnant and postpartum women with multiple sclerosis receiving ocrelizumab or other disease-modifying therapies
-
- Journal Article
- A1
- open access
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic
-
- Journal Article
- A1
- open access
Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation
-
Redefining the Multiple Sclerosis Severity Score (MSSS) : the effect of sex and onset phenotype